About 2,260 results

ALLMedicine™ Acid Phosphatase Center

Research & Reviews  884 results

DNA damage-inducible transcript 3 restrains osteoclast differentiation and function.
Bone Yang B, Sun H et. al.

Aug 30th, 2021 - DNA damage-inducible transcript 3 (DDIT3), a member of the CCAAT/enhancer-binding protein (C/EBP) family, is involved in cellular apoptosis and differentiation. DDIT3 participates in the regulation of adipogenesis and osteogenesis in vitro and in ...

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in pa...
Journal for Immunotherapy of Cancer; Pachynski RK, Morishima C et. al.

Aug 29th, 2021 - Sipuleucel-T (sip-T) is a Food and Drug Administration (FDA)-approved autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). We hypothesized that combining sip-T with interleukin (IL)-7, a homeostatic cytoki...

Extraction and characterization of matrix protein from pacific oyster (Crassostrea gigs...
Food & Function; Feng X, Jiang S et. al.

Aug 14th, 2021 - Matrix protein is a kind of secretory protein that regulates the biomineralization of the bivalve shell. In this study, a water-soluble matrix protein (WSMP) from Pacific oysters (Crassostrea gigs) shell was isolated, and its structure was analyze...

Bone responsiveness to parathyroid hormone is negatively associated with parathyroid ho...
BMC Nephrology; Tominaga N, Yonaha T et. al.

Aug 11th, 2021 - Parathyroid hormone (PTH) acts on bone to indirectly increase the number and activity of osteoclasts. Thus, PTH has a stimulatory effect on bone resorption and upregulates bone turnover. However, the responsiveness of bone to PTH varies widely amo...

Osteoclastic activity in chronic otitis media with cholesteatoma-related bone destruction.
The Journal of Laryngology and Otology; Özgür A, Yemiş T et. al.

Aug 6th, 2021 - Cholesteatoma-related bone destruction is the cause of many complications due to chronic otitis media. This study aimed to evaluate osteoclastic activity in cholesteatoma-related bone destruction using tartrate-resistant acid phosphatase 5b, an en...

see more →

Drugs  3 results see all →

News  17 results

Sequential IV Ibandronate Tied to BMD Increase

Dec 9th, 2020 - NEW YORK (Reuters Health) - Monthly intravenous ibandronate is associated with increases in bone mineral density (BMD) and bone microstructure benefits in women with osteoporosis after teriparatide treatment, according to new findings. Once teripa...

Romosozumab Has Biggest Effect in Treatment-Naive Patients

Aug 21st, 2020 - NEW YORK (Reuters Health) - Postmenopausal women with osteoporosis who are treatment-naive have the greatest early response to romosozumab (ROMO), according to new research. Improvements in lumbar spine (LS) and femoral neck (FN) bone-mineral dens...

Management of Castration-Resistant Prostate Cancer

Apr 3rd, 2019 - Treatment of Metastatic CRPC (M1 Disease) As with M0 CRPC, ADT should be continued in patients with mCRPC to maintain castration levels of testosterone while initiating additional treatments. Several drugs for the treatment of mCRPC have been appr.

Rethinking the Prostate Cancer Paradigm in the Urology Community

Aug 4th, 2018 - Raoul S. Concepcion, MD, FACS As we are all keenly aware, there is not a day that passes when our email inbox doesn’t include news of a genetic discovery that contributes to the ever-expanding body of knowledge in the prostate cancer world. The pr...

DNA vaccine + PD-1 blockade shows promise in mCRPC
Sharon Worcester

Dec 9th, 2017 - NATIONAL HARBOR, MD. – Combining programmed death (PD)-1 blockade with tumor-targeted T-cell activation by a novel DNA vaccine safely enhanced antitumor immune responses in metastatic castration-resistant prostate cancer (mCRPC) patients in a rand.

see more →